Newsbenzinga
FDA Approval Nearly Doubles Eligible Patient Pool For Novartis' Pluvicto
· Published
Article summary
FDA approves Novartis' Pluvicto for earlier-stage metastatic prostate cancer, nearly doubling eligible patients.
An excerpt from the original article.
Comments —
Loading comments…